Selective androgen receptor modulators, plus non-SARM compounds commonly grouped with them (MK-677, GW-501516, SR9009, AICAR, SLU-PP-332). Each profile states the actual mechanism.
Nucleoside analog and AMPK activator, studied for reproducing molecular effects of exercise on metabolism.
PPAR-delta agonist developed by GlaxoSmithKline and Ligand Pharmaceuticals, studied for effects on endurance and fatty-acid metabolism.
Non-steroidal selective androgen receptor modulator developed by Ligand Pharmaceuticals, studied for anabolic activity in muscle and bone research.
Non-steroidal selective androgen receptor modulator developed by GTx, studied for muscle preservation in wasting-condition research.
Non-steroidal selective androgen receptor modulator developed by Radius Health, studied for anabolic activity with reduced androgenic effect.
Non-steroidal selective androgen receptor modulator developed by GTx, studied for anabolic activity in muscle and bone research.
Rev-ErbA agonist developed at Scripps Research, studied for effects on circadian rhythm and metabolic activity.
Steroidal selective androgen receptor modulator that also acts as a myostatin inhibitor, studied in muscle research.
